These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 32585249)

  • 1. Alzheimer's disease; a review of the pathophysiological basis and therapeutic interventions.
    Abeysinghe AADT; Deshapriya RDUS; Udawatte C
    Life Sci; 2020 Sep; 256():117996. PubMed ID: 32585249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid metabolism and Alzheimer's disease: pathways and possibilities.
    Saxena U
    Expert Opin Ther Targets; 2009 Mar; 13(3):331-8. PubMed ID: 19236155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. beta-Amyloid as a molecular therapeutic target in Alzheimer's disease.
    Adlard PA; James SA; Bush AI; Masters CL
    Drugs Today (Barc); 2009 Apr; 45(4):293-304. PubMed ID: 19499094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current druggable targets for therapeutic control of Alzheimer's disease.
    Gupta GL; Samant NP
    Contemp Clin Trials; 2021 Oct; 109():106549. PubMed ID: 34464763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toward an early diagnosis and treatment of Alzheimer's disease.
    Nordberg A
    Int Psychogeriatr; 2003 Sep; 15(3):223-37. PubMed ID: 14756159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinued disease-modifying therapies for Alzheimer's disease: status and future perspectives.
    Imbimbo BP; Lozupone M; Watling M; Panza F
    Expert Opin Investig Drugs; 2020 Sep; 29(9):919-933. PubMed ID: 32657175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reducing Aβ load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease.
    Kalra J; Khan A
    Eur J Pharmacol; 2015 Oct; 764():571-581. PubMed ID: 26209363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Case for a Novel Therapeutic Approach to Dementia: Small Molecule Hepatocyte Growth Factor (HGF/MET) Positive Modulators.
    Moebius HJ; Church KJ
    J Alzheimers Dis; 2023; 92(1):1-12. PubMed ID: 36683507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic strategies.
    Chen Y; Fu AKY; Ip NY
    Pharmacol Ther; 2019 Mar; 195():186-198. PubMed ID: 30439458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tea polyphenols as multi-target therapeutics for Alzheimer's disease: An in silico study.
    Mazumder MK; Choudhury S
    Med Hypotheses; 2019 Apr; 125():94-99. PubMed ID: 30902161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of tau-directed small molecule modulators for Alzheimer's disease: a recent patent review (2014-2018).
    Lee HE; Lim D; Lee JY; Lim SM; Pae AN
    Pharm Pat Anal; 2019 Jan; 8(1):15-39. PubMed ID: 30870110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurodegenerative Pathways in Alzheimer's Disease: A Review.
    Ramachandran AK; Das S; Joseph A; Shenoy GG; Alex AT; Mudgal J
    Curr Neuropharmacol; 2021; 19(5):679-692. PubMed ID: 32851951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The past, present, and future of disease-modifying therapies for Alzheimer's disease.
    Suzuki K; Iwata A; Iwatsubo T
    Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(10):757-771. PubMed ID: 29225305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptides isolated from animal venom as a platform for new therapeutics for the treatment of Alzheimer's disease.
    Camargo LC; Campos GAA; Galante P; Biolchi AM; Gonçalves JC; Lopes KS; Mortari MR
    Neuropeptides; 2018 Feb; 67():79-86. PubMed ID: 29198480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein-Protein Interactions and Aggregation Inhibitors in Alzheimer's Disease.
    Ganeshpurkar A; Swetha R; Kumar D; Gangaram GP; Singh R; Gutti G; Jana S; Kumar D; Kumar A; Singh SK
    Curr Top Med Chem; 2019; 19(7):501-533. PubMed ID: 30836921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alzheimer's disease drug development based on Computer-Aided Drug Design.
    Zeng H; Wu X
    Eur J Med Chem; 2016 Oct; 121():851-863. PubMed ID: 26415837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease.
    Muñoz-Torrero D
    Curr Med Chem; 2008; 15(24):2433-55. PubMed ID: 18855672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationally Designed Peptides and Peptidomimetics as Inhibitors of Amyloid-β (Aβ) Aggregation: Potential Therapeutics of Alzheimer's Disease.
    Goyal D; Shuaib S; Mann S; Goyal B
    ACS Comb Sci; 2017 Feb; 19(2):55-80. PubMed ID: 28045249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deciphering Alzheimer's disease: predicting new therapeutic strategies via improved understanding of biology and pathogenesis.
    Khoury R; Grossberg GT
    Expert Opin Ther Targets; 2020 Sep; 24(9):859-868. PubMed ID: 32603232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer's Disease.
    Mukhopadhyay S; Banerjee D
    J Alzheimers Dis; 2021; 83(4):1537-1552. PubMed ID: 34366359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.